Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the four analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $4.33.

A number of equities research analysts have weighed in on ONCY shares. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Oncolytics Biotech in a report on Wednesday, May 21st. Jones Trading reaffirmed a "hold" rating on shares of Oncolytics Biotech in a report on Friday, May 16th. Royal Bank Of Canada decreased their price objective on Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating on the stock in a report on Monday, March 10th. Finally, Maxim Group decreased their price objective on Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating on the stock in a report on Monday, March 10th.

Oncolytics Biotech Stock Up 14.4%

Shares of ONCY opened at $0.90 on Friday. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.53. The firm has a market capitalization of $84.95 million, a price-to-earnings ratio of -3.11 and a beta of 1.07. The stock's 50-day moving average price is $0.55 and its 200 day moving average price is $0.66.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. Equities research analysts expect that Oncolytics Biotech will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ONCY. Virtu Financial LLC acquired a new position in shares of Oncolytics Biotech in the 4th quarter worth approximately $90,000. National Bank of Canada FI boosted its holdings in shares of Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock worth $60,000 after acquiring an additional 42,955 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Oncolytics Biotech by 59.6% in the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock worth $61,000 after acquiring an additional 24,997 shares in the last quarter. 6.82% of the stock is owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.